ESMO, the leading professional organisation for medical oncology, has granted the newly established ESMO Award for Immuno-Oncology to Prof Laurence Zitvogel for her innovating and internationally recognised achievements in the field.
LUGANO, Switzerland, 19 October 2017 - ESMO, the leading professional organisation for medical oncology, has granted the newly established ESMO Award for Immuno-Oncology to Prof Laurence Zitvogel for her innovating and internationally recognised achievements in the field.
"Prof Zitvogel's discoveries in the area of immuno-oncology have served as the foundation for important advances and our understanding of the fundamentals of cancer immunology," said Christoph Zielinski of the ESMO Fellowship and Award Committee. "In presenting her with this award we are recognising her preeminent and pioneering role in the field," noted Zielinski.
Zitvogel, MD, PhD, is professor of Immunobiology at the University of Paris XI Medical School and scientific director at the Department of Immuno-Oncology, Gustave Roussy Cancer Centre, Villejuif, France. She is director of the U1015 INSERM Tumour Immunology and Immunotherapy Laboratory at INSERM and co-director of the Centre for Clinical Investigation in Biotherapies of Cancer, INSERM.
The ESMO Award for Immuno-Oncology will be presented during the ESMO Immuno-Oncology Congress 2017 [http://www.esmo.org/Conferences/ESMO-Immuno-Oncology-Congress-2017] in Geneva, on 7 December, with the keynote lecture “Introducing the gut microbiome into the complexity of anticancer immunosurveillance”.
Laurence Zitvogel has dedicated her career to advancing the field of cancer immunology and immunotherapy. She is a dedicated educator having directed the work of many postdoctoral fellows. She has authored or co-authored over 350 publications. She is Editor-in-Chief and founder of one of the first journals in immuno-oncology, “OncoImmunology.”
Zitvogel said: “I am honoured to receive this award, which acknowledges the work of, not only my team and Gustave Roussy colleagues, but also that of the European pioneers who relentlessly paved the way for the relevance of the immune system in long-term cures obtained in patients treated with chemotherapy, radiotherapy and immune-targeted antibodies.”
Full story: http://bit.ly/2yretO2
About the European Society for Medical Oncology (ESMO)
ESMO is the leading professional organisation for medical oncology. With 17,000 members representing oncology professionals from 150 countries worldwide, ESMO is the society of reference for oncology education and information, committed to supporting members to develop and advance in a fast-evolving professional environment.